v3.26.1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance at Dec. 31, 2024 $ 250,504 $ 22 $ 1,855,318 $ 14 $ (1,604,850)
Beginning balance (in shares) at Dec. 31, 2024   223,923      
Fees incurred related to common stock financings (171)   (171)    
Vesting of restricted stock (in shares)   960      
Exercise of stock options 1,127 $ 1 1,126    
Exercise of stock options (in shares)   580      
Stock-based compensation expense 7,022   7,022    
Unrealized loss on marketable securities, net (14)     (14)  
Net loss (49,389)       (49,389)
Ending balance at Mar. 31, 2025 209,079 $ 23 1,863,295   (1,654,239)
Ending balance (in shares) at Mar. 31, 2025   225,463      
Beginning balance at Dec. 31, 2025 $ 160,884 $ 27 2,009,845 28 (1,849,016)
Beginning balance (in shares) at Dec. 31, 2025 266,732 266,732      
Fees incurred related to common stock financings $ (125)   (125)    
Exercise of pre-funded warrants (in shares)   2,192      
Vesting of restricted stock (in shares)   864      
Exercise of stock options $ 59   59    
Exercise of stock options (in shares) 29 29      
Stock-based compensation expense $ 5,662   5,662    
Unrealized loss on marketable securities, net (30)     (30)  
Net loss (47,210)       (47,210)
Ending balance at Mar. 31, 2026 $ 119,240 $ 27 $ 2,015,441 $ (2) $ (1,896,226)
Ending balance (in shares) at Mar. 31, 2026 269,817 269,817